A Clinical Trial of an Investigational COVID-19 Vaccine

*Note: Patients must live within a 1-hour drive of Nashville, Tennessee.

The NextCOVE Study is a Phase 3 clinical trial conducted by Moderna to evaluate an investigational vaccine that may protect people from getting sick if they come into contact with the virus that causes COVID-19, including the XBB.1.5 variant. For more information, please scroll past the form.

Please Complete This Form, And Our Team Will Reach Out To You As Soon As Possible to Discuss the Study in Detail.

Your Name:(Required)

First Last

Child's Name (If Applicable)

First Last

Your Email(Required)

Your Phone Number(Required)

How would you describe yourself? Please check all that apply.

Alaska Native

American Indian

Asian

Black or African American

Native Hawaiian or Other Pacific Islander

White

Hispanic or Latino or Spanish Origin

Prefer Not to Say

CAPTCHA

Trial Details

The NextCOVE Study is evaluating mRNA-1283.815, one of Moderna’s investigational vaccines that may protect people from getting sick if they come into contact with the virus that causes COVID-19. Moderna will be studying this new investigational vaccine in children and adults to learn more about how it works in the body.

You, along with up to 33,574 other individuals, will be helping researchers learn more about Moderna’s latest investigational vaccine that may help protect people from getting sick if they come into contact with the virus.

Eligibility Criteria

Participants must:

Be at least 65 years old
Be willing and able to comply with trial requirements

Participants must not:

Have had a positive COVID-19 test within 3 months prior to the screening visit
Have been exposed to someone with SARS-CoV-2 infection or COVID-19 within 2 weeks prior to receiving the first vaccination
Have received a COVID-19 vaccine within 3 months prior to the screening visit

What to Expect

Participation in the NextCOVE Study will last approximately 13 months and includes up to 7 visits to a trial site and 3 safety phone calls.

You or your child will be chosen at random to receive either mRNA-1273.815 or the investigational dose of mRNA-1283.815. By comparing the vaccines, medical researchers can better understand how well the investigational vaccine works.

All trial participants will receive the same level of quality care regardless of which vaccine they receive.

You or your child will also be asked to complete electronic diary (eDiary) entries for the duration of the trial to report any COVID-19 symptoms that may occur.

Insurance is not needed to participate, and qualified participants will receive payment for their trial-related time and travel.